Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated...
Aptinyx Announces Pricing of Public Offering of Common Stock EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system...
Kit Check’s Bluesight for Controlled Substances™ Named Category Leader for Drug Diversion Monitoring in 2020 Best in KLAS Report KLAS report ranks Kit Check as the top performer with 93.9 rating for consistently delivering on product support, customer loyalty and...
BrightInsight Announces Global Digital Health Partnership with AstraZeneca AstraZeneca selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment SAN JOSE, Calif., March 25, 2020 (GLOBE NEWSWIRE)...
Key customer wins, rapidly growing customer base, and bold product vision accelerate TigerConnect’s role as a force of change for Healthcare collaboration SANTA MONICA, California — Jan. 29, 2020 — TigerConnect, healthcare’s most advanced, reliable, and widely adopted...
Recent Comments